about
Beta-blockers for hypertensionBeta-blockers for hypertensionCarvedilol in hypertension treatmentUse of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studiesBeta-Blockers in the Management of Hypertension and/or Chronic Kidney Diseaseβ-Blockers in hypertension, diabetes, heart failure and acute myocardial infarction: a review of the literatureThe cost-effectiveness of drug treatments for primary prevention of cardiovascular disease: a modelling studyCardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysisRole of angiotensin II in cardiovascular disease therapeutic implications of more than a century of researchBeta-blockers for hypertension.Comparative effectiveness of antihypertensive medication for primary prevention of cardiovascular disease: systematic review and multiple treatments meta-analysis.Does atenolol differ from other beta-adrenergic blockers?Therapy: atenolol versus metoprolol tartrate--conflicting outcomes data.Do advertisements for antihypertensive drugs in Australia promote quality prescribing? A cross-sectional study.Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST).Optimal use of beta-blockers in high-risk hypertension: a guide to dosing equivalenceHypertension management: an update.Central blood pressure: current evidence and clinical importance.Pathophysiologic therapeutic targets in hypertension: a cardiological point of view.Prehypertension: Underlying pathology and therapeutic options.Recurrent stroke: what have we learnt?Achieved blood pressures in the secondary prevention of small subcortical strokes (SPS3) study: challenges and lessons learned.Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis.The potential economic impact of restricted access to angiotensin-receptor blockersClinical utility of fixed-dose combinations in hypertension: evidence for the potential of nebivolol/valsartan.Antihypertensive agents in hemodialysis patients: a current perspective.Commentary on recent guidelines for treating hypertension.A randomized controlled study on the effects of bisoprolol and atenolol on sympathetic nervous activity and central aortic pressure in patients with essential hypertension.Hypertension in the elderly: Are we all on the same wavelength?When not to use beta-blockers in seniors with hypertensionIndications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular riskMedical reversal: why we must raise the bar before adopting new technologiesAcute β-adrenergic blockade increases aortic wave reflection in young men and women: differing mechanisms between sexes.Variation among cardiovascular risk calculators in relative risk increases with identical risk factor increases.Beta blockers in hypertension and cardiovascular disease.The implications of a growing evidence base for drug use in elderly patients Part 2. ACE inhibitors and angiotensin receptor blockers in heart failure and high cardiovascular risk patients.Use of carvedilol in hypertension: an update.Treatment of systemic hypertension.The burden and management of cytochrome P450 2D6 (CYP2D6)-mediated drug-drug interaction (DDI): co-medication of metoprolol and paroxetine or fluoxetine in the elderly.Is amlodipine the best initial monotherapy for hypertension?
P2860
Q24201511-755259B8-4061-4D55-91FB-98ED35689F8EQ24202812-1CDDED11-5889-48F0-89FC-090B26BD9FFFQ24642654-BFDF33BC-3609-440A-849F-D0F75C2BFF8DQ24658205-7F9F84FC-82D6-47C8-982D-4B54C42C98BBQ26825409-2147749A-67CC-4F3C-AE19-1E4DF28C5FB5Q26861630-E0D40326-A361-41E5-9A17-6F3E659513BCQ28199830-37E80163-DC2E-4F47-BCE5-A02DF5BC1F0DQ28200196-6EA7B984-5549-4481-AC26-4387AD5E380FQ28272171-1A582386-F818-42B0-82EF-D88D72F7890CQ30238911-A0255529-5BFA-430F-8682-AB34FF8E273DQ30514101-FD42D689-D92D-4B1C-99D5-C3C3E25815F4Q30831411-C22ADEDB-6591-450F-A590-A4FA579D30AAQ30848706-2B09B54D-F4D3-4A63-BCEA-D941DDCB450DQ33336223-DCD24B3B-93FD-4843-A451-B57CC945BA73Q33586456-AF1D0B61-4DAE-46AE-A320-83C2BE5D1C0FQ33902595-0A2CE990-0CC8-4BF5-8F3E-B4537EC59471Q33932224-DD722AA5-1369-4C6C-91FB-2EC92495464DQ34137689-4B6BB21E-9824-4B0E-B37E-2F89A65CC1C4Q34142036-2A377F7F-0474-4661-8C87-CD461C362362Q34179007-9D0C75AB-F2B9-44EC-AD3B-C77BA44BF9FBQ34220533-2D841D43-7475-4E25-9FA8-BB5FE5A8CB29Q34285841-F2BF4D1E-AECE-4786-9CC1-DCD289859B06Q34380070-7568EFAE-4C1A-44C2-A46F-C351F88A1B64Q34590001-E2B55996-58DB-4DAD-BAC5-A172D817CE0FQ34609451-9A1B7084-B123-4C26-970B-158329D401EEQ34700870-962A1394-8F2C-404E-B157-527CDE28C383Q34974314-DF5B1B2B-793D-4109-B891-D8923657A57EQ34988304-5AB15993-FBFD-41FC-8EF7-8AA391E6B0F5Q35185094-898C5C0A-C123-48E0-AB75-7080148F8430Q35246527-EB9BB97A-789F-49DC-8995-C76D5438B8C4Q35539305-AE908189-1CD5-4A63-BCBF-CE883B69129BQ35614816-392A2E76-0EA2-426D-8218-F08ECB48B4DEQ35621708-E5095376-EC6D-47D2-8B1B-1103A1B73A48Q35766315-DCC0C317-4478-478C-91AD-39F6B81BC915Q35782957-337F87CC-2CC0-4346-A1B1-1A799D390D90Q35827554-25817AC1-13BD-491B-85E4-768C31F5E3CAQ35997307-0B277637-F0B4-4E59-A710-52A33E03E5E8Q36190285-F6709274-E143-4596-965D-5C4414347209Q36323469-1FD79205-310B-4FC0-92CF-21FFEA78E0CDQ36429760-B2CFA4B7-E033-4163-96EE-28D4461972ED
P2860
description
2004 nî lūn-bûn
@nan
2004 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Atenolol in hypertension: is it a wise choice?
@ast
Atenolol in hypertension: is it a wise choice?
@en
type
label
Atenolol in hypertension: is it a wise choice?
@ast
Atenolol in hypertension: is it a wise choice?
@en
prefLabel
Atenolol in hypertension: is it a wise choice?
@ast
Atenolol in hypertension: is it a wise choice?
@en
P2093
P1433
P1476
Atenolol in hypertension: is it a wise choice?
@en
P2093
Bo Carlberg
Lars Hjalmar Lindholm
Ola Samuelsson
P304
P356
10.1016/S0140-6736(04)17355-8
P407
P577
2004-11-01T00:00:00Z